CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results
Participants may access the live audio webcast of the teleconference from the “Investors & News” section of CytomX’s website at http://ir.cytomx.com/. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.
Audio Conference Call:
U.S. Dial-in Number: | (877) 809-6037 | |
International Dial-in Number: | (615) 247-0221 | |
Conference ID: | 1686972 |
An archived webcast replay will be available on the Company's website from
About
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential best-in-class immunotherapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult to drug targets. Five novel drug-candidates utilizing our Probody technology are in clinical trials, with three in Phase 2 studies and two in Phase 1. These clinical programs include cancer immunotherapies against validated targets such as a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting Probody therapeutic partnered with
PROBODY is a registered trademark of
Contact:
Investors and Media:
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823
Source: CytomX Therapeutics Inc.